Loading...
•
Sep 30, 2021
Myriad Genetics Q3 2021 Earnings Report
Announced third quarter 2021 results, demonstrating strong execution of strategic growth & transformation plans.
Key Takeaways
Myriad Genetics reported a 15% year-over-year increase in revenue to $167.3 million for the third quarter of 2021. Excluding revenue from divested businesses, revenue increased 27% year-over-year. Diluted GAAP EPS was $0.30, while adjusted EPS was $(0.02).
Revenue of $167.3 million, up 15% year-over-year (27% excluding divested businesses).
Diagnostic test volumes increased 15% year-over-year to 252,000.
Diluted GAAP EPS of $0.30 and adjusted EPS of $(0.02).
Ended the quarter with $413.6 million in cash, cash equivalents and investments.
Revenue by Segment
Forward Guidance
Due to the continued unpredictability surrounding the COVID-19 pandemic, the company will not provide financial guidance for the fourth quarter ending December 31, 2021 or fiscal year 2021. The company expects to resume providing financial guidance in early 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...